Inoviq Ltd · ASX:IIQ
Inoviq — Shareholder Meeting (November 2023)
22 slides from Inoviq's shareholder meeting presentation, Nov 29, 2023
Slide 1: CEO Presentation - Annual General Meeting 2023
CEO Presentation Annual General Meeting 2023 Leearne – this is a concept. I like it! Let me know what you think. We would need to buy the image / do the label better if you are okay with using this. ASX: IIQ | 29 November 2023
Slide 2: Disclaimer
Disclaimer This presenta tion has been prepa red by INOVIQ Limi ted (“INOVIQ” or the “Company”) Actual resul ts , performance or a chievements could be signi fi cantl y different from those based on i nforma tion a vailable to i tas at the date of this presenta tion. This presenta tion expressed in,
Slide 3: Company snapshot
Company snapshot $ Financial information (ASX:IIQ) Precision Disruptive Deep Ordinary shares2 92,018,702 focus technology pipeline Listed options 2 2,611,349 52-week H/L2 A$0.990-0.460 Precision diagnostic and Proprietary technology Multi-stage pipeline exosome solutions to platforms driving future
Slide 4: Key achievements FY2023 to date
Key achievements FY2023 to date Nicoya Direct sales model BARD1 legal Positive EXO-NET EXO-NET R&D and collaboration to established for proceeding feasibility in OC manufacturing Progressed evaluate hTERT in US settled study centralised to EXO-NET SubB2M SPR test Melbourne lab pipeline Patents, publ
Slide 5: 3 business pillars
3 business pillars | Research tools, diagnostics and therapeutics 5
Slide 6: Products and pipeline
Products and pipeline | multi-stage research tools and cancer diagnostics • Exosome research tools for exosome isolation, biomarker discovery and diagnostics development • Blood tests for earlier and more accurate detection of breast, ovarian and other cancers PRODUCT INDICATION USE RESEARCH ASSAY C
Slide 7: Exosomes | diagnostic and therapeutic potential
Exosomes | diagnostic and therapeutic potential • Exosomes are released by cells and perform key roles in intercellular communication, immune regulation and pathogenesis • Diseases elicit changes in the release of exosomes and their molecular cargo (DNA, RNA and proteins) • Exosomes can be isolated
Slide 8: EXO-NET | exosome isolation tools
EXO-NET® | exosome isolation tools Immunoaffinity magnetic bead-based capture system for isolation and analysis of exosomes Rapid, Simple, Compatible downstream Cost-effective analysis Enriches relevant EVs Reproducible Scalable Compatible with path Full automation lab workflow and platforms cGMP 8
Slide 9: EXO-NET research tools and services | commercially available
EXO-NET research tools and services | commercially available EXO-NET PAN- CUSTOMISED EXOSOME BIOMARKER DIAGNOSTICS EXOSOME CAPTURE EXO-NET TOOLS ISOLATION DISCOVERY DEVELOPMENT EXO-NET is a research Design custom EV isolation using Biomarker discovery EV-based clinical tool for fast, efficient & EXO
Slide 10: SubB2M technology platform
SubB2M technology platform Scientific rationale • Aberrant glycosylation (adding sugars) is a hallmark of cancer • Neu5Gc is a sugar molecule commonly found in cancer cells, but not healthy normal cells • SubB2M is an engineered protein that preferentially binds to Neu5Gc, making it a promising mult
Slide 11: SubB2M/CA15-3 test | Breast Cancer monitoring
SubB2M/CA15-3 test | Breast Cancer monitoring Clinical-stage and progressing towards partner-ready by Dec 2023 to enable LDT commercialisation • #1 cancer in women Development stage Breast cancer • 2.3m new cases of breast cancer worldwide pa 1 • 7.8m survivors (5-year)1 Feasibility Completed • Non-
Slide 12: SubB2M/CA15-3 test | data and plans
SubB2M/CA15-3 test | data and plans SubB2M/CA15-3 and comparator CA15-3 test Clinical validation study | completed performance summary Breast Cancer All Stages SubB2M Comparator • Retrospective, case-control, clinical validation study in 483-samples AUC 0.93 0.70 demonstrated SubB2M/CA15-3 test dete
Slide 13: Breast cancer monitoring study | Study 1 design
Breast cancer monitoring study | Study 1 design Study 1: To determine whether NeuCA15-3 is equally expressed in women with different subtypes of breast cancer comparison between Pre-treatment serum types of BC Hormone receptor breast cancer (n=50) SubB2M/CA15-3 test Her2 positive breast cancer (n=50
Slide 14: Breast cancer monitoring study | Study 2 design
Breast cancer monitoring study | Study 2 design Study 2: To determine the accuracy of SubB2M/CA15-3 to identify breast cancer recurrence comparison between recurrence and non- recurrence SubB2M/CA15-3 test no recurrent disease (n=12) comparison between test recurrent disease (n=12) IVD CA15-3 test 1
Slide 15: SubB2M/CA125 test | Ovarian Cancer monitoring
SubB2M/CA125 test | Ovarian Cancer monitoring Progressing towards clinical validation • #8 cancer in women & deadliest gynaecological cancer Development stage Ovarian cancer • 314k new cases of ovarian cancer worldwide pa 1 • 823k survivors (5-year)1 Feasibility Completed • Non-invasive, earlier and
Slide 16: EXO-OC test | Exosome-based Ovarian Cancer screening
EXO-OC test | Exosome-based Ovarian Cancer screening 1,2,3 Developing an accurate and reliable test for early detection of ovarian cancer • #8 cancer in women & deadliest gynaecological cancer Development stage Ovarian cancer • 314k new cases of ovarian cancer worldwide pa 4 • 823k survivors (5-year
Slide 17: Diagnostics | go-to-market strategy
Diagnostics | go-to-market strategy SubB2M/CA15-3 test is expected to be partner-ready in December 2023 for commercialisation as a Laboratory Developed Test Complete IVD Secure IVD partners Commercialise first medical device Build analytical and approvals as an LDT in the USA and clinical developmen
Slide 18: SubB2M tests | workflow
SubB2M tests | workflow Collection Centre Routine Pathology Laboratory transit @ 4OC Routine venipuncture Serum collected Standard Autoanalyzer SubB2M tests are fully compatible with existing pathology laboratory workflow Sample Report 18
Slide 19: Market potential | screening and monitoring tests
Market potential | screening and monitoring tests Eligible screening Eligible monitoring Statistics1 Global Market size 4,5 population2 population3 11.5 4.0 Ovarian cancer incidence 188.3 52,638 60.4 6 Ovarian 119m 367k $1.9b 54.7 GLOBAL Dx cancer 167.3 MARKET Ovarian cancer prevalence 154,831 (Mill
Slide 20: Milestones and catalysts
Milestones and catalysts SubB2M and EXO-NET programs moving towards key inflection points H2 CY 2023 H1 CY 2024 ✓ EXO-NET co-marketing agreement with Promega Commercial progress SubB2M/CA15-3 LDT ✓ Results of EXO-OC equivalence study in plasma and serum (n=250) Results SubB2M/CA125 OC clinical valid
Slide 21: Summary | Next generation diagnostic solutions advancing towards key milestones
Summary | Next generation diagnostic solutions advancing towards key milestones 1 Innovative 2 Patented 3 Strong 4 Compelling Company Technology Pipeline Results Focused on next-gen diagnostic Proprietary SubB2M & NETs Deep pipeline Data for SubB2M and exosome- and exosome solutions to technologies
Slide 22: Contacts
Contacts INOVIQ Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@inoviq.com W www.inoviq.com Dr Leearne Hinch | CEO E lhinch@inoviq.com M +61 400414416 22